Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Colloidal silicon dioxide (SiO2), also known as fumed silica, is a submicroscopic, amorphous powder with a particle size of approximately 15 nm. It is characterized by being light, odorless, tasteless, and bluish-white. In the pharmaceutical industry, it serves multiple roles as a versatile excipient, including as a glidant to enhance powder flowability in tablet and capsule manufacturing, an anti-caking agent, an adsorbent, a disintegrant, an emulsion stabilizer, a suspending agent, and a thickening agent. It possesses hygroscopic properties, allowing it to absorb significant amounts of liquid without liquefying. Beyond its excipient functions, colloidal silicon dioxide is also investigated for its therapeutic applications as an enterosorbent, particularly in the treatment of acute diarrhea, where it functions by adsorbing pathogenic microorganisms, toxins, and allergens from the gastrointestinal tract.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on colloidal silicon dioxide.